Efficacy of infliximab in refractory Behçet's disease-associated and idiopathic posterior segment uveitis: A prospective, follow-up study of 50 patients

Biologics: Targets and Therapy

Volumn 6, Issue , 2012, Pages 5-12

  Cantini, Fabrizio ^a   Niccoli, Laura ^a   Nannini, Carlotta ^a   Kaloudi, Olga ^a   Cassarà, Emanuele ^a   Susini, Massimo ^b   Lenzetti, Ivo ^b  

^a Second Division of Internal Medicine   (Italy)

^b Prato Hospital   (Italy)

Author keywords

Beh et's disease; Idiopathic posterior uveitis; Infliximab; Posterior uveitis; Visual acuity

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LIVER ENZYME; METHOTREXATE; PREDNISONE;

ADULT; ARTICLE; BEHCET DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INFUSION; DRUG INFUSION REACTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; LUPUS LIKE SYNDROME; MALE; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; REMISSION; RETINA MACULA CYSTOID EDEMA; SIDE EFFECT; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UVEITIS; VISUAL ACUITY;

EID: 84856726561     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Perkins ES, Folk J. Uveitis in London and Iowa. Ophthalmologica. 1984;189:36-40.
2. Henderly DE, Genstler AJ, Smith RE, Rao NA. Changing patterns of uveitis. Am J Ophthalmol. 1987;103:131-136.
3. Weiner A, BenEzra D. Clinical patterns and associated conditions in chronic uveitis. Am J Ophthalmol. 1991;112:151-158.
4. Rodriguez A, Calonge M, Pedroza-Seres M, et al. Referral patterns of uveitis in a tertiary eye care center. Arch Ophthalmol. 1996;114:593-599.
5. Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140:509-516.
6. Rathinam SR, Namperumalsamy P. Global variation and pattern changes in epidemiology of uveitis. Indian J Ophthalmol. 2007;55(3):173-183.
7. Kaçmaz RO, Kempen JH, Newcomb C, et al. Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol. 2008;146:828-836.
8. Kump LI, Moeller KL, Reed GF, Kurup SK, Nussenblatt RB, Levy-Clarke GA. Behçet's disease: comparing 3 decades of treatment response at the National Eye Institute. Can J Ophthalmol. 2008;43: 468-472.
9. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138:373-380.
10. Pato E, Muñoz-Fernández S, Francisco F, Abad MA, Maese J, Ortiz A, et al. Systematic review on the effectiveness of immunosuppressants and biological therapies in the treatment of autoimmune posterior uveitis. Semin Arthritis Rheum. 2011;40:314-323.
11. Ilhan F, Demir T, Türkçüoǧlu P, Turgut B, Demir N, Gödekmerdan A. Th1 polarization of the immune response in uveitis in Behçet's disease. Can J Ophthalmol. 2008;43:105-108.
12. Ahad MA, Missotten T, Abdallah A, Lympany PA, Lightman S. Polymorphisms of chemokine and chemokine receptor genes in idiopathic immune-mediated posterior segment uveitis. Mol Vis. 2007;13:388-396.
13. Okada AA, Sakai J, Usui M, et al. Intraocular cytokine quantifcation of experimental autoimmune uveoretinitis in rats. Ocul Immunol Inflamm. 1998;6:111-120.
14. Calder VL, Shaer B, Muhaya M, et al. Increased CD4+ expression and decreased IL-10 in the anterior chamber in idiopathic uveitis. Invest Ophthalmol Vis Sci. 1999;40:2019-2024.
15. Robertson M, Liversidge J, Forrester J V, et al. Neutralizing tumor necrosis factor-alpha activity suppresses activation of infiltrating macrophages in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci. 2003;44:3034-3041.
16. Greiner K, Murphy CC, Willermain F, et al. Anti-TNFalpha therapy modulates the phenotype of peripheral blood CD4+ T cells in patients with posterior segment intraocular inflammation. Invest Ophthalmol Vis Sci. 2004;45:170-176.
17. Santos Lacomba M, Marcos Martin C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 2001;33:251-255.
18. Larson T, Nussenblatt RB, Sen HN. Emerging drugs for uveitis. Expert Opin Emerg Drugs. 2011;16:309-322.
19. Niccoli L, Nannini C, Benucci M, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: a 24-month follow-up study. Rheumatology (Oxford). 2007;46(7):1161-1164.
20. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492-513.
21. International Study Group for Behçet's disease. Criteria for diagnosis of Behçet's disease. Lancet. 1990;335:1078-1080.
22. Tugal-Tutkun I. Behçet's uveitis. Middle East Afr J Ophthalmol. 2009;16:219-224.
23. Goossens PH, Verburg RJ, Breedveld FC. Remission of Behçet's syndrome with tumour necrosis factor alpha blocking therapy. Ann Rheum Dis. 2001;60:637.
24. Muñoz-Fernández S, Hidalgo V, Fernández-Melón J, Schlincker A, Martín-Mola E. Effect of infliximab on threatening panuveitis in Behçet's disease. Lancet. 2001;358:1644.
25. Triolo G, Vadalà M, Accardo-Palumbo A, et al. Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behçet's disease. Ann Rheum Dis. 2002;61:560-561.
26. Morris DS, Gavin M P, Sturrock RD. The effect of anti-tumour necrosis factor alpha (infliximab) on sight-threatening uveitis in a patient with Behçet's disease. Adv Exp Med Biol. 2003;528:557-559.
27. Giansanti F, Barbera ML, Virgili G, Pieri B, Emmi L, Menchini U. Infliximab for the treatment of posterior uveitis with retinal neovascu-larization in Behçet disease. Eur J Ophthalmol. 2004;14:445-448.
28. Takamoto M, Kaburaki T, Numaga J, Fujino Y, Kawashima H. Long-term infliximab treatment for Behçet's disease. Jpn J Ophthalmol. 2007;51:239-240.
29. Olivieri I, Latanza L, Siringo S, Peruz G, Di Iorio V. Successful treatment of severe Behçet's disease with infliximab in an Italian Olympic athlete. J Rheumatol. 2008;35:930-932.
30. Olivieri I, Padula A, Leccese P, D'Angelo S, Giasi V. Long-lasting remission of severe Behçet's disease after the end of infliximab therapy. J Rheumatol. 2009;36:855.
31. Alokaily F, Alsaleh S, Al-Balawi M, Al-Rashidi S. Efficacy of infix-imab on the acute attack of uveitis. Saudi Med J. 2010;31:82-85.
32. Donghi D, Mainetti C. Infliximab for the treatment of refractory Adamantiades-Behçet disease with articular, intestinal, cerebral and ocular involvement. Dermatology. 2010;220:282-286.
33. Kawaguchi T, Sugita S, Yamada Y, Miyanaga M, Mochizuki M. Regression of optic disc neovascularization in patients with Behçet's uveoretinitis after infliximab therapy. J Ocul Pharmacol Ther. 2010;26:627-630.
34. Sfikakis P P, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet. 2001;358:295-296.
35. Joseph A, Raj D, Dua HS, Powell PT, Lanyon PC, Powell RJ. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology. 2003;110:1449-1453.
36. Sfkakis P P, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med. 2004;140:404-406.
37. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362-1368.
38. Wechsler B, Sablé-Fourtassou R, Bodaghi B, et al. Infliximab in refractory uveitis due to Behçet's disease. Clin Exp Rheumatol. 2004;22(4 Suppl 34):S14-S16.
39. Benitez-del-Castillo JM, Martinez-de-la-Casa JM, Pato-Cour E, et al. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab). Eye (Lond). 2005;19:841-845.
40. Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. Arthritis Rheum. 2005;52:2478-2484.
41. Lindstedt E W, Baarsma GS, Kuijpers RW, van Hagen PM. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol. 2005;89:533-536.
42. Lanthier N, Parc C, Scavennec R, Dhôte R, Brézin A P, Guillevi L. Infliximab in the treatment of posterior uveitis in Behçet's disease. Long term follow up in four patients. Presse Med. 2005;34:916-918.
43. Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005;123:903-912.
44. Mushtaq B, Saeed T, Situnayake RD, Murray PI. Adalimumab for sight-threatening uveitis in Behçet's disease. Eye (Lond). 2007;21:824-825.
45. Abu El-Asrar AM, Abboud EB, Aldibhi H, Al-Arfaj A. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease. Int Ophthalmol. 2005;26:83-92.
46. Accorinti M, Pirraglia M P, Paroli M P, Priori R, Conti F, Pivetti-Pezzi P. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease. Jpn J Ophthalmol. 2007;51:191-196.
47. Tognon S, Graziani G, Marcolongo R. Anti-TNF-alpha therapy in seven patients with Behçet's uveitis: advantages and controversial aspects. Ann N Y Acad Sci. 2007;1110:474-484.
48. Al-Rayes H, Al-Swailem R, Al-Balawi M, Al-Dohayan N, Al-Zaidi S, Tariq M. Safety and efficacy of infliximab therapy in active Behçet's uveitis: an open-label trial. Rheumatol Int. 2008;29:53-57.
49. Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease. Am J Ophthalmol. 2008;146:845-850.
50. Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M. Comparison of infliximab versus cyclosporin during the initial 6-month treatment period in Behçet disease. Br J Ophthalmol. 2010;94:284-288.
51. Giardina A, Ferrante A, Ciccia F, Vadalà M, Giardina E, Triolo G. One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet's disease refractory to standard immunosuppressive drugs. Rheumatol Int. 2011;31:33-37.
52. Adán A, Hernandez V, Ortiz S, et al. Effects of infliximab in the treatment of refractory posterior uveitis of Behçet's disease after withdrawal of infusions. Int Ophthalmol. 2010;30(5):577-581.
53. Yamada Y, Sugita S, Tanaka H, Kamoi K, Takase H, Mochizuki M. Timing of recurrent uveitis in patients with Behcet's disease receiving infliximab treatment. Br J Ophthalmol. 2011;95:205-208.
54. Sugita S, Yamada Y, Mochizuki M. Relationship between serum infliximab levels and acute uveitis attacks in patients with Behçet disease. Br J Ophthalmol. 2011;95:549-552.
55. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80:332-336.
56. Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P, Murray PI. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol. 2004;88:1159-1162.
57. Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Sugar EA. The Multicenter Uveitis Steroid Treatment Trial Research Group, The multicenter uveitis steroid treatment trial: rationale, design and baseline characteristics. Am J Ophthalmol. 2010;149:550-561.
58. Kempen JH, Ganesh SK, Sangwan VS, Rathinam SR. Interobserver agreement in grading activity and site of inflammation in eyes of patients with uveitis. Am J Ophthalmol. 2008;146:813-818.
59. Tugal-Tutkun I, Cingu K, Kir N, Yeniad B, Urgancioglu M, Gul A. Use of laser fare-cell photometry to quantify intraocular inflammation in patients with Behçet's uveitis. Graefes Arch Clin Exp Ophthalmol. 2008;246:1169-1177.
60. Sfkakis P P. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun. 2010;11:180-210.
61. Markomichelakis NN, Theodossiadis PG, Pantelia E, Papaefthimiou S, Theodossiadis G P, Sfkakis P P. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol. 2004;138:648-650.
62. de Vries J, Baarsma GS, Zaal MJW, et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. Br J Ophthalmol. 1990;74:344-349.